Drug Discovery AI Generative Models is applying deep learning to design novel drug molecules with desired properties, accelerating discovery and reducing costs in pharmaceutical development — AI dramatically speeds drug design. Generative models create chemical space. Molecular Representations SMILES strings: text representation of molecules (e.g., CCO = ethanol). Advantages: trainable with NLP methods. Limitations: syntax constraints. Molecular graphs: atoms/bonds as nodes/edges. Graph neural networks naturally process graphs. Graph Neural Networks for Molecules message passing neural networks process molecular graphs. Node features (atom type, charge), edge features (bond type). Permutation invariant: output independent of atom ordering. Generative Adversarial Networks (GANs) GAN generator creates new molecules, discriminator distinguishes real from generated. Adversarial training balances generation and realism. Variational Autoencoders (VAE) encoder maps molecules to latent space, decoder generates molecules from latent codes. Latent space continuous—interpolation between molecules. Reinforcement Learning for Generation treat molecule generation as sequential decision: at each step, choose atom/bond to add. RL reward based on desired properties (drug-likeness, activity, synthesis feasibility). Property Prediction neural networks predict molecular properties (binding affinity, solubility, toxicity). Trained on experimental data. Guide generation towards favorable properties. Scaffold Hopping find new scaffolds maintaining desired properties. Graph-based methods constrain generation to scaffold class. Multi-Objective Optimization design molecules optimizing multiple objectives: potency, selectivity, safety, synthesis cost, off-target effects. Pareto frontier approaches. Synthesis Feasibility generated molecules might be impossible or expensive to synthesize. Machine learning models predict synthesis difficulty. Incorporate feasibility into generation objective. SMILES Tokenization break SMILES into tokens (atoms, bonds), apply seq2seq models. Hybrid approach combining text and graph. Transformer Models seq2seq transformers generate SMILES conditioned on desired properties. Encode property, decode SMILES. Attention visualizes which properties influence which atoms. Physics-Informed Models incorporate domain knowledge: valency constraints, periodic table properties. Reduces invalid molecule generation. Active Learning iteratively select most informative molecules to synthesize/test. Reduce experimental cost. Transfer Learning pretrain on large unlabeled molecule databases, finetune on drug discovery task. Molecular Similarity find similar molecules to hits for lead optimization. Fingerprints, graph similarity, embedding distance. Known Drug Database Integration leverage existing drugs as context. Don't rediscover known actives. Novelty metrics. Lead Optimization improve hit compounds: increase potency, selectivity, reduce toxicity, improve ADMET (absorption, distribution, metabolism, excretion, toxicity). Structure-activity relationship (SAR) learning. Fragment-Based Generation generate molecules from chemical fragments. Ensures generated molecules decompose into known fragments. Natural Product Generation generative models trained on natural products mimic natural chemistry. Generate biologically-plausible molecules. Enzyme Engineering design mutations improving enzyme function. Graph representations capture protein structure. Clinical Validation AI-designed molecules eventually tested in animals then humans. Validate AI enables real drug discovery. Applications cancer drugs, antibiotics (against resistant bacteria), rare genetic diseases, personalized medicine. Timeline Acceleration AI potentially reduces drug discovery from 10+ years to significantly faster. Drug discovery AI transforms pharmaceutical industry enabling faster, cheaper drug development.